Loading company…
Repron Therapeutics develops epigenetic therapies targeting residual tumor cells and micro-metastases.
Founded in 2023 and based in Milan, Italy, Repron Therapeutics develops engineered synthetic factors intended to inhibit oncogene activity. Its approach aims to target residual tumor cells and micro-metastases in cases where complete surgical removal is not feasible. In June 2023, it raised EUR 2 million in seed funding led by Claris Ventures, with participation from Consiglio National Research Council (CNR) and San Raffaele Hospital Srl.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in